Furthermore, because CGA is known to influence MAPK and PI3K/Akt signaling pathways [96], combination therapy with Regorafenib has been explored [97], which is a multikinase inhibitor used in the treatment of refractory advanced colon cancer [98]. Here, AKT1 is linked to malignant colon neoplasm.